78485-37-7

Basic information

• Product Name: Ethyl 2-chloro-6-benzothiazolecarboxylate
• Synonyms: Ethyl2-chlorobenzo[d]thiazole-6-carboxylate;2-Chlorobenzothiazole-6-carboxylic acid ethyl ester;Ethyl 2-chloro-6-benzothiazolecarboxylate
• CAS NO: 78485-37-7
• Molecular Formula: C₁₀H₈ClNO₂S
• Molecular Weight: 241.69
• Mol File: 78485-37-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 90-92°
• Boiling Point: 340.5 °C at 760 mmHg
• Flash Point: 159.7 °C
• Appearance: /
• Density: 1.400
• Vapor Pressure: 8.58E-05mmHg at 25°C
• Refractive Index: 1.635
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.37±0.10(Predicted)
• CAS DataBase Reference: Ethyl 2-chloro-6-benzothiazolecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-chloro-6-benzothiazolecarboxylate(78485-37-7)
• EPA Substance Registry System: Ethyl 2-chloro-6-benzothiazolecarboxylate(78485-37-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 78485-37-7(Hazardous Substances Data)

Usage

General Description

Ethyl 2-chloro-6-benzothiazolecarboxylate, also known as Ethyl 2-chloro-6-(phenylthio)benzothiazole-7-carboxylate, is a chemical compound with the molecular formula C13H9ClNOS. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. Ethyl 2-chloro-6-benzothiazolecarboxylate has also been identified as a potential anti-cancer agent, with studies showing its ability to inhibit the growth of cancer cells. Additionally, it has been found to possess anti-inflammatory and anti-fungal properties, making it a versatile compound with potential applications in various fields. However, it is important to handle this chemical with care, as it is classified as a hazardous substance and can cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C10H8ClNO2S/c1-2-14-9(13)6-3-4-7-8(5-6)15-10(11)12-7/h3-5H,2H2,1H3

Upstream product

• 50850-93-6 ethyl 2-aminobenzothiazole-6-carboxylate 
• 94-09-7 p-aminoethylbenzoate 
• 73792-12-8 ethyl 4-amino-3-fluorobenzoate 

Downstream Products

• 1383739-48-7 ethyl 2-(4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)benzo[d]thiazole-6-carboxylate 
• 1383739-80-7 ethyl 2-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)piperidin-1-yl)benzo[d]thiazole-6-carboxylate 
• 1383739-81-8 2-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)piperidin-1-yl)benzo[d]thiazole-6-carboxylic acid 
• 1383739-59-0 C₂₉H₂₈F₃N₃O₄S 
• 1383739-76-1 C₃₀H₃₀F₃N₃O₅S 

Relevant articles and documents

Benzothiazole derivatives and medical application thereof

The invention discloses benzothiazole derivatives and a medical application thereof. The invention provides a series of benzothiazole derivatives, and research finds that the series of benzothiazole derivatives can effectively improve the expression level

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS

The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hype

FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.